The effect of antiretroviral treatment of different durations in primary HIV infection

AIDS

Volumn 22, Issue 18, 2008, Pages 2441-2450

  Pantazis, Nikos ^a   Touloumi, Giota ^a   Vanhems, Philippe ^b,c   Gill, John ^d   Bucher, Heiner C ^e   Porter, Kholoud ^f  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c UNIVERSITÉ DE LYON   (France)

^d Southern Alberta Clinic   (Canada)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

CD4 cell loss; Primary HIV infection; Short course ART; Viral set point

Indexed keywords

ABACAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL LEVEL; CELL LOSS; CONTROLLED STUDY; CYTOMETRY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY INFECTION; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADOLESCENT; ADULT; AGE FACTORS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 57349121049     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328319ea4e     Document Type: Article

References (35)

1. Markowitz M, Vesanen M, Tenner-Racz K. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999;179:527-537.
2. Carcelain C, Blanc C, Leibowitch J, Mariot P, Mathez D, Schneider V, et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS 1999;13:1077-1081.
3. Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. AIDS 2000;4:243-249.
4. Smith DM, Berrey MM, Robertson M, Mehrotra D, Markowitz M, Perrin L, et al. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000;182:950-954.
5. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
6. Cameron DW, Heatn-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998;351:543-549.
7. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8(+) and CD4(+) T lymphocytes. Proc Natl Acad Sci USA 2000;97:3382-3387.
8. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001;193:169-180.
9. Berrey MM, Schacker T, Collier AC, Shea T, Brodie SJ, Mayers D, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001;183:1466-1475.
10. Hoen B, Dumon B, Harzic M, Venet A, Dubeaux B, Lascoux C, et al. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. J Infect Dis 1999;180:1342-1346.
11. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-526.
12. Rosenberg ES, BillingsleyJM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4(+) T cell responses associated with control of viremia. Science 1997;278:1447-1450.
13. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;333:450-451.
14. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. 2007; 42-43. Available at http://www.aidsinfo.nih.- gov/ContentFiles/AdultandAdolescentGL.pdf.
15. Clumeck N, EACS Euroguidelines Grp. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003;17 (Suppl 2):3-26.
16. Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C, Chaix ML, et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004;18:2361-2369.
17. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002;186:634-643.
18. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J Acquir Immune Defic Syndr 1999;21:114-119.
19. Carr A, Samaras K, Burton S, Law M, Freund), Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
20. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
21. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of Protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - a 5-year cohort study. Arch Intern Med 2000;160:2050-2056.
22. Paterson DL, Swindells S, Mohr J, BresterM, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
23. Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JA. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 2004;18:709-718.
24. Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, Babiker A, et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002;16:2049-2054.
25. Bhaduri S, Miller AR. Response to 'Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence' by Smith et al. AIDS 2004;18:2448.
26. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000;1:224-231.
27. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. Oxford: Oxford University Press; 1994.
28. Vittinghoff E, Malani HM, Jewell NP. Estimating patterns of CD4 lymphocyte decline using data from a prevalent cohort of HIV-1 infected individuals. Stat Med 1994;13:1101-1118.
29. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000;181:872-880.
30. Phillips AN, Lee CA, Elford J, Janossy G, Kernoff PB. The cumulative risk of AIDS as the CD4 lymphocyte count declines. J Acquir Immune Defic Syndr 1992;5:148-152.
31. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983;2:267-271.
32. Clements M, Law M, Pedersen C, Kaldor J, CASCADE Collaboration. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data. HIV Med 2003;4:332-337.
33. Touloumi G, Hatzakis A. Natural history of HIV-1 infection. Clin Dermatol 2000;18:389-399.
34. Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006;194:725-733.
35. Fidler S, Fox J, Touloumi G, Pantazis N, Porter K, Babiker A, et al. Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIDS 2007;21:1283-1291.